airbufo forspiro 160 micrograme/4,5 micrograme
aeropharm gmbh - germania - combinatii (budesonidum+formoterolum) - pulb. de inhal. unidoza - 160micrograme/4,5micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
everio airmaster 50 micrograme/500 micrograme
oy medfiles ltd. - finlanda - salmeterolum+fluticasonum - pulb. de inhal. unidoza - 50micrograme/500micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
strepsils intensiv miere si lamaie 8,75 mg/doza
rb nl brands b.v - olanda - flurbiprofenum - spray bucofaringian, sol. - 8,75mg/doza - medicamente pentru zona oro-faringiana medicamente pentru zona oro-faringiana
airbufo forspiro 320 micrograme/9 micrograme
lek farmacevtska druba d.d. - slovenia - combinatii (budesonidum+formoterolum) - pulb. de inhal. unidoza - 320micrograme/9micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
strepsils intensiv cirese si menta 8,75 mg/doza
rb nl brands b.v. - olanda - flurbiprofenum - spray bucofaringian, sol. - 8,75mg/doza - medicamente pentru zona oro-faringiana medicamente pentru zona oro-faringiana
strepsils intensiv cireșe și mentă 8,75 mg/doză spray bucofaringian, soluţie
reckitt benckiser (romania) srl - flurbiprofenum - spray bucofaringian, soluţie - 8,75 mg/doză
everio airmaster 50 mcg/500 mcg pulbere de inhalat unidoză
zentiva k.s. - salmeterolum + fluticasonum - pulbere de inhalat unidoză - 50 mcg/500 mcg
adempas
bayer ag - riociguat - hipertensiune arterială, pulmonară - antihipertensive pentru hipertensiunea arterială pulmonară - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. eficacitatea a fost demonstrată într-un hap populației, inclusiv etiologii ale idiopatică sau ereditară pah sau htap asociată bolilor de țesut conjunctiv. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.